FY2025 EPS Estimates for Genmab A/S Boosted by William Blair

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Research analysts at William Blair upped their FY2025 earnings estimates for Genmab A/S in a note issued to investors on Friday, November 7th. William Blair analyst M. Phipps now forecasts that the company will post earnings of $1.97 per share for the year, up from their prior estimate of $1.75. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S’s Q4 2025 earnings at $0.47 EPS and FY2028 earnings at $2.74 EPS.

A number of other equities research analysts also recently weighed in on GMAB. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. HC Wainwright boosted their price objective on Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a report on Monday. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Truist Financial reaffirmed a “buy” rating and issued a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $39.75.

Genmab A/S Stock Performance

Shares of GMAB opened at $30.31 on Monday. The business’s fifty day moving average price is $29.78 and its two-hundred day moving average price is $24.62. The firm has a market capitalization of $19.46 billion, a price-to-earnings ratio of 12.90, a PEG ratio of 1.51 and a beta of 0.96. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $33.65.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Orbis Allan Gray Ltd increased its stake in Genmab A/S by 38.7% in the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Genmab A/S by 152.3% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after buying an additional 2,084,966 shares during the period. First Trust Advisors LP grew its holdings in shares of Genmab A/S by 3.5% in the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock valued at $36,575,000 after buying an additional 60,504 shares during the period. Brandywine Global Investment Management LLC increased its position in shares of Genmab A/S by 1.6% in the 2nd quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock valued at $36,047,000 after buying an additional 27,372 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after buying an additional 665,893 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.